Evidence map›Paper›PMID 29987034›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Monitoring disease activity noninvasively in the

Antonio Filareto, Katie Maguire-Nguyen, Qiang Gan, Garazi Aldanondo, Léo Machado, Jeffrey S Chamberlain, Thomas A Rando

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Transplantation to study satellite cell heterogeneity in skeletal muscle.Frontiers in cell and developmental biology · 2022
    Review
  2. Review
  3. Skeletal muscle in health and disease.Disease models & mechanisms · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Antonio FilaretoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Katie Maguire-NguyenDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Qiang GanDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305.
Garazi AldanondoNeuroscience Area, Biodonostia Research Institute, 20014 San Sebastian, Spain.
Léo MachadoFaculte de Medecine, Universite Paris Est Creteil, 94000 Creteil, France.
Jeffrey S ChamberlainDepartment of Neurology, Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, University of Washington School of Medicine, Seattle, WA 98195.
Thomas A RandoDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305; rando@stanford.edu.
Stanford University · USBiogipuzkoa Health Research Institute · ESMuscular Dystrophy Association · USUniversité Paris-Est Créteil · FRVA Palo Alto Health Care System · US

Funding

DYSTROPHIN REPLACEMENT IN MDX MICER01AR040864 · NIAMS · UNIVERSITY OF WASHINGTON · PI JEFFREY S CHAMBERLAIN · 1991 to 2026
$8.8M
Notch Signaling and Satellite Cell ActivationR37AG023806 · NIA · STANFORD UNIVERSITY · PI RANDO, THOMAS A. · 2010 to 2019
$2.9M
Complement Components as Mediators of Cell and Tissue AgingR01AG055755 · NIA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI RANDO, THOMAS A. · 2017 to 2021
$2.2M
Regulation of Muscle Fibrosis in Response to Injury and AgingI01BX002324 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI RANDO, THOMAS A. · 2014 to 2021
–
Muscle Stem Cell Therapy for Volumetric Muscle LossI01RX001222 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI HUANG, NGAN F. · 2014 to 2023
–
BLRD VA I01 BX002324NIAMS NIH HHS R01 AR040864NIA NIH HHS R01 AG055755NIA NIH HHS R37 AG023806RRD VA I01 RX001222
6 · The paper itself

Abstract

Duchenne muscular dystrophy (DMD) is a rare, muscle degenerative disease resulting from the absence of the dystrophin protein. DMD is characterized by progressive loss of muscle fibers, muscle weakness, and eventually loss of ambulation and premature death. Currently, there is no cure for DMD and improved methods of disease monitoring are crucial for the development of novel treatments. In this study, we describe a new method of assessing disease progression noninvasively in the

Indexed as

DependovirusDystrophinGenetic TherapyMuscle Fibers, SkeletalMuscular Dystrophy, DuchenneTransduction, GeneticAnimalsHumansMiceMice, TransgenicDystrophinBLIDMDmonitoring disease activitymuscle degenerationmuscle regeneration

Identifiers

PMID29987034
PMCPMC6064991
OpenAlexW2848516563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.